Pellegrino Musto

55PUBLICATIONS
258CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Aug 27, 2026
The Dysregulation of the Integrated Stress Response in Leukemic Stem Cells as a Marker of Treatment Sensitivity in Acute Myeloid Leukemia.

|Aug 19, 2026
Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.

|Aug 18, 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

|Jan 07, 2026
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna

|Aug 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|Jun 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595.

Nicola Sgherza, Olga Battisti, Paola Curci

Pageof 10

Frequent Collaborators

15 joint publications

Francesco Albano

10 joint publications

Francesca Gay

8 joint publications

Cosimo Cumbo

7 joint publications

Francesco Tarantini